title: Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.
abstract: OBJECTIVE
  Clozapine and risperidone were the first two antipsychotic drugs of a new class of agents for the pharmacotherapy of schizophrenia. It has been suggested that refractory schizophrenic patients who fail to respond to neither clozapine nor risperidone may respond to a combination/augmentation strategy of both medicaments.
  
  
  METHODS
  Three cases of individuals with unremittent schizophrenia treated via this combination are presented. Response was evaluated by clinical follow-up and PANSS rating scale.
  
  
  RESULTS
  Good clinical results with no noticeable adverse side effects, ascertained by a reduction from baseline scores of the Positive and Negative Syndrome Scale (PANSS) were obtained in all three patients.
  
  
  CONCLUSIONS
  The findings from this pilot study suggest this combination as a possible therapeutic approach for treating resistant schizophrenic patients.
authors.affiliation: The Kfar Shaul Mental Health Center, Jerusalem, Israel.
authors.forename: S
authors.initials: S
authors.lastname: Raskin
authors.forename: G
authors.initials: G
authors.lastname: Katz
authors.forename: Z
authors.initials: Z
authors.lastname: Zislin
authors.forename: H Y
authors.initials: HY
authors.lastname: Knobler
authors.forename: R
authors.initials: R
authors.lastname: Durst
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003024:Clozapine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine; D018967:Risperidone